Encontrados 5 documentos, a visualizar página 1 de 1
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Ar...
Aymon, Romain; Mongin, Denis; Guemara, Romain; Salis, Zubeyir; Askling, Johan; Choquette, Denis; Codreanu, Catalin; Di Giuseppe, Daniela; Flouri, IriniFunding Information: Supported by AbbVie, Galapagos, Pfizer, and Eli Lilly. Publisher Copyright: © 2025 The Author(s). Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.; Objective: Our objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor ne...
Impact of patient characteristics on ASDAS disease activity state cut-offs in a...
Ørnbjerg, Lykke M.; Georgiadis, Stylianos; Kvien, Tore K.; Michelsen, Brigitte; Rasmussen, Simon; Pavelka, Karel; Zavada, Jakub; Loft, Anne GittePublisher Copyright: © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.; OBJECTIVES: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a la...
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyl...
Christiansen, Sara Nysom; Rasmussen, Simon Horskjær; Ostergaard, Mikkel; Pons, Marion; Michelsen, Brigitte; Pavelka, Karel; Codreanu, CatalinFunding Information: Novartis Pharma AG for supporting the EuroSpA collaboration. The paper has been presented at the Scandinavia Congress of Rheumatology 2023 as an oral presentation and at the EULAR 2023 Congress as a poster presentation (POS0656) with the following abstract: SNC, SHR, LMO, etc. Does radiographic status impact secukinumab effectiveness in European axial spondyloarthritis patients treated in r...
Differences and similarities between the EULAR/ASAS-EULAR and national recommen...
Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Ørnbjerg, Lykke Midtbøll; Zavada, JakubFunding Information: The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG . Novartis had no influence on the data collection, analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2023 The Author(s); This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decad...
Spectrum of lymphomas across different drug treatment groups in rheumatoid arth...
Mercer, Louise K.; Regierer, Anne C.; Mariette, Xavier; Dixon, William G.; Baecklund, Eva; Hellgren, Karin; Dreyer, Lene; Hetland, Merete LundFunding: Individual registries had entered into agreements with pharmaceutical companies (AbbVie, BMS, Hospira, MSD, Pfizer, Roche, UCB, Samsung and Eli Lilly). The pharmaceutical companies funding these registers were, however, not involved in the planning of the project, the statistical analyses, the interpretation of the results or the decision to publish.; BACKGROUND: Lymphomas comprise a heterogeneous grou...